Skip to main content

Advertisement

Table 2 Results of area under the curve of CGM and glucose fluctuations at STEP 0 and at the end of this protocol

From: Improvement of both fasting and postprandial glycemic control by the two-step addition of miglitol and mitiglinide to basal insulin therapy: a pilot study

  At the evaluation of STEP 0 At the end of this protocol
Results of continuous glucose monitoring   
Number of patients 14 14
AUC for 24-h glycemic fluctuation (mg・h/dL) 4112.1 2986.3*
(3568.8-4338.5) (2843.3-3504.0)
AUC for 4-h after breakfast glycemic fluctuation (mg・h/dL) 732.3 521.5*
(607.4-845.4) (498.9-626.9)
AUC for 4-h after lunch glycemic fluctuation (mg・h/dL) 785.9 516.2*
(573.5-952.0) (466.5-550.6)
AUC for 4-h after dinner glycemic fluctuation (mg・h/dL) 785.3 559.2*
(719.4-877.8) (485.3-651.4)
AUC for 8-h from midnight to early morning glycemic fluctuation (00:00–08:00) (mg・h/dL) 1033.0 949.8
(911.4-1187.5) (869.6-1074.3)
24-h mean glucose levels (mg/dL) 169.7 124.7*
(142.6-181.1) (118.8-146.4)
SDs of 288 glucose levels for 24-h (mg/dL) 38.6 23.5*
(29.9-58.5) (13.9-28.4)
Proportion of time (%) in hyperglycemia (>180 mg/dL) 40.7 7.9*
(17.4-53.7) (0–17.2)
Proportion of time (%) in hypoglycemia (<70 mg/dL) 0 0
MAGE 91.1 (79.1-119.6) 61.3* (50.2-72.4)
Results of 7-point SMBG   
Number of patients 16 16
M-value 28.8 (21.4-52.5) 8.7 *(5.0-15.7)
  1. Median (interquartile range)
  2. *P < 0.05
  3. CGM data were analyzed in a total of 14 patients because of missing CGM data in 2 of the 16 patients.